What is included in this Sample?
- * Market Segmentation
- * Key Findings
- * Research Scope
- * Table of Content
- * Report Structure
- * Report Methodology
Download FREE Sample Report
Prenatal Screening Market Size, Share, Growth, and Industry Analysis, By Type (First-Trimester Screening Tests, Second-Trimester Screening Tests, Third-Trimester Screening Tests, Diagnostic Tests and Others), By Application (Hospitals, Gynecology Clinics, Research Organizations and Others), Regional Forecast To 2033
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
PRENATAL SCREENING MARKET OVERVIEW
The prenatal screening market stood at approximately USD 5.22 billion in 2024 and is projected to expand to USD 5.79 billion in 2025, eventually reaching USD 11.99 billion by 2033, driven by a CAGR of 11% from 2025 to 2033.
Prenatal testing and newborn screening tests are diagnostic procedures that are used to detect any potential birth problems in the infant. Prenatal screening aims to detect issues in a wide population using inexpensive and noninvasive technologies. Prenatal diagnosis is more invasive and focused on obtaining more precise information if a specific condition has been identified. Routine ultrasounds, blood tests, and blood pressure measurements are the most often used screening methods. Amniocentesis and chorionic villus collection are both common diagnostic procedures. The increasing prevalence of genetic problems in infants aided in the expansion of the prenatal testing and newborn screening market.
COVID-19 IMPACT
Pandemic Caused Lockdown led in Upsurge of the Market Demand
The COVID-19 outbreak is expected to enhance the prenatal screening market share due to the business world's embrace of prenatal screening technology to promote efficiency, transparency, popularity, and reliability. The COVID-19 pandemic epidemic increased the demand on hospitals to speed up and expand their testing capabilities. The market under study saw growth in vendor development of automation systems as a result of the daily increase in the number of foetus examined, which is anticipated to open up new potential for market expansion.
LATEST TRENDS
The Use of Machine Learning and Artificial Intelligence to Uplift the Market Demand
The application of machine learning and artificial intelligence is progressively gaining traction in the prenatal testing and newborn screening sector. Artificial intelligence (AI) is the simulation of human intelligence in machines. Machine learning is a subset of AI. Machine learning and AI assist organisations in the prenatal testing and newborn screening sector in conducting a complete analysis of all relevant data, providing insights about various disorders, and providing a more accurate evaluation of tissue samples.
For example, Sema4, a US-based AI-driven genomic and clinical data intelligence platform firm, will debut Sema4 Elements in September 2021. Sema4 Elements are information-driven genetic solutions, digital platforms for patients and providers, and services that enable doctors to manage patients holistically across their reproductive and generational health journeys using artificial intelligence.
PRENATAL SCREENING MARKET SEGMENTATION
By Type Analysis
Based on type, the prenatal screening market is classified into first-trimester screening tests, second-trimester screening tests, third-trimester screening tests, diagnostic tests and other.
The first trimester screening tests is the leading part of the type segment.
By Application Analysis
Based on application, the prenatal screening market is classified into hospitals, gynecology clinics, research organizations and others.
The hospitals is the leading part of the application segment.
DRIVING FACTORS
The Prior Knowledge and Deep Rooted Information Offered by Screening to the Parents will Boost the Market Growth
Other family members with these disorders may be known to one or both partners. Prior to conception, testing may alleviate anxiety, prepare the couple for the potential short- or long-term repercussions of having a child with the disease, direct the couple towards adoption or foster parenting, or induce preimplantation genetic testing during in vitro fertilisation. In certain situations, the tests are used to determine whether or not the pregnancy will be aborted, but physicians and patients also find them valuable in detecting high-risk pregnancies early so that birth can be arranged in a tertiary care hospital where the infant can receive adequate treatment.
High Prevalence of Genetic Diseases in Infants to Strengthen the Market Structure
The market for prenatal testing and newborn screening has expanded as a result of the increased prevalence of genetic disorders in infants. Genetic disorders include conditions including Thalassemia, Sickle Cell Anaemia, Haemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, and Huntington's disease, according to the World Health Organization. One of the genetic diseases that affects millions of individuals worldwide is sickle cell anaemia, which is more prevalent in those whose ancestors originated in Africa, America, Cuba, Central America, Saudi Arabia, and India.
RESTRAINING FACTORS
Lack of Insufficient Healthcare Access and Low Disposable Income to Hamper the Market Demand
Prenatal screening market growth may be impeded by the relatively low healthcare availability in most developing countries compared to industrialised countries. In India, for example, there were only roughly 1.9 million hospital beds for 1.33 billion people in 2020. Limited access to healthcare services, as well as a scarcity of hospitals and healthcare experts, have hampered market expansion in many developing countries. Furthermore, limited disposable income in many countries reduces access to healthcare facilities, stifling the expansion of the prenatal screening market share.
-
Request a Free sample to learn more about this report
PRENATAL SCREENING MARKET REGIONAL INSIGHTS
North American Region Gauge for the Huge Revenue Share with Well Established Healthcare Infrastructure
In 2020, the North American region dominated the market for prenatal screening, accounting for more than a quarter of all revenues. This dominance is anticipated to continue throughout the forecast period. The expansion is ascribed to the region's well maintained and established healthcare infrastructure. Additionally, the local presence of significant firms and the favourable reimbursement system in this area are promoting the prenatal screening market growth. Due to the presence of all the major industry players and strict FDA restrictions, the market is quite competitive in the nation. The nation's businesses are using robotics and automation in labs more and more to gain an edge over the development. Such elements are expected to boost regional prenatal screening market share.
KEY INDUSTRY PLAYERS
Notable Players contributing towards the market
The market's expansion was significantly impacted by the techniques employed by market participants in recent years, such as extensions. The report covers details and information about the firms and their interactions with the market.
List of Top Prenatal Screening Companies
- Laboratory Corporation of America Holdings (U.S.A)
- Sequenom (U.S.A)
- Quest Diagnostics (U.S.A)
- Illumina (U.S.A)
- GeneDx (U.S.A)
- Ariosa Diagnostics (U.S.A)
- Natera (U.S.A)
- Ravgen (U.S.A)
- Counsyl (U.S.A)
- Eurofins NTD (Europe)
- Premaitha Health (U.K)
- Prenatal Paternities (U.K).
INDUSTRY DEVELPEMENT
- In March 2020: Thermo Fisher Scientific Inc announced its intention to acquire Qiagen for $11.5 billion. Thermo Fisher has a specialist diagnostics capacity that covers allergy, autoimmune, transplant diagnostics, and oncology testing. The acquisition is intended to enhance Thermo Fisher's genetic analysis and bioscience capabilities.
REPORT COVERAGE
The report is an analysis of all market aspects for the forecast period. It also shows the evaluation of opportunities, trends, market share, product innovations, technology innovations, driving factors, restraints and others that contribute towards the market growth. This report covers a comprehensive backdrop analysis, an assessment of the parent market, intensive study in the market dynamics. Past historical, current, and projected size of the market from the point of both value and volume. Researching of recent industry developments, deep study on market shares and strategies of major players and the emerging niche segments and regional market areas are covered in the report.
Attributes | Details |
---|---|
Market Size Value In |
US$ 5.22 Billion in 2024 |
Market Size Value By |
US$ 11.99 Billion by 2033 |
Growth Rate |
CAGR of 11% from 2025 to 2033 |
Forecast Period |
2025-2033 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The global prenatal screening market is expected to touch USD 11.99 billion by 2033.
The prenatal screening market is expected to exhibit a CAGR of 11% over forecast period.
The North American region leads the prenatal screening market.
The prior knowledge and deep rooted information offered by screening to the parents and high prevalence of genetic disease in infants are the driving factors of the prenatal screening market.
Laboratory Corporation of America Holdings, Sequenom, Quest Diagnostics, Illumina, GeneDx, Ariosa Diagnostics, Natera, Ravgen, Counsyl, Eurofins NTD, Premaitha Health, Prenatal Paternities and others are the top companies operating in the prenatal screening market.